环孢素治疗银屑病并发天疱疮一例

银屑病并发天疱疮临床少见,两种疾病治疗存在矛盾。该例患者有银屑病病史7年,20 d前出现水疱、糜烂;皮损组织病理及疱病自身抗体检查支持寻常性银屑病并发寻常性天疱疮诊断,给予口服环孢素及外用药物治疗后病情改善。     

环孢素治疗难治性银屑病1例

1病历摘要 患者男,36岁.因全身反复出现红斑、丘疹、鳞屑12年,加重10余天,于2003年9月30日来本院诊治.患者12年前无明显诱因双下肢出现散在红斑、丘疹、鳞屑伴瘙痒,随后扩展至全身,给予口服中药(具体不详)、雷公藤多苷及外用糖皮质激素后好转,但反复发作.5年前自服甲氨蝶呤2.5mg,每日1次,服用1个月余.半年前肌内注射曲安奈德20 mg,每周1次,连续注射2个月,治疗期间皮疹有所消退,停药后约10 d皮疹再次加重,泛发至全身,且融合成片.随后在当地医院给予中药、雷公藤多苷片、甘草酸二铵等治疗无效.10 d前因上呼吸道感染,伴高热,体温达40℃,皮损加重伴双膝关节疼痛而入院.     

环孢素治疗银屑病概况

环孢素治疗银屑病概况普雄明综述石得仁审校（新疆维吾尔自治区人民医院皮肤科８３０００１）环孢素作为一种独特的免疫调节剂，国外约在１９８４年开始用于严重银屑病的治疗〔１〕，由于此药价格昂贵，国内应用较少，但随着国民经济的发展和人民收入的增加，国内应用也逐...     

银屑病治疗新进展

银屑病治疗新进展袁广文（天津市蓟县人民医院皮肤科，３０１９００）银屑病的发病机理目前尚不明了，其治疗方法虽多，但大多数只能达近期疗效，不能控制复发。乙双吗啉、维甲酸、外用皮质类固醇激素等虽有一定疗效，但其副作用较大或价格过高而不能广泛应用于临床。近年...     

短期小剂量应用环孢菌素A治疗银屑病

环孢菌素A(CyclosporinA,简称CyA)是新一代的非细胞毒性免疫抑制药物,在抑制体液和细胞介导的免疫反应及慢性炎症中效果明显,近年来在抑制器官移植后的排斥反应及治疗多种自身免疫性疾病中应用较多[1]。国内外学者曾报道过局部注射或口服CyA治疗各种类型的银屑病[2～6],然而,对CyA治疗银屑病的剂量、疗程及副作用等尚无明显的认识。因此有必要探讨CyA的剂量与疗效、临床症状改善速度及所需时间之间的关系。本文应用短期小剂量CyA,对5例不同类型的顽固性银屑病进行了治疗观察,报告如下。材料和方法一、病例选择　详见表1。5例患者均为1…     

环孢素A免疫疗法治疗银屑病

银屑病是一种常见皮肤病，多数病人需要长期治疗。银屑病属于免疫性皮炎，其发病机理与Ｔ淋巴细胞密切相关。近１０年来采用环孢素Ａ治疗银屑病取得很好疗效。本文就新山地明的剂型，环孢素Ａ治疗银屑病的适应症与禁忌症，环孢素Ａ治疗银屑病、银屑病亚型的疗效、毒副反应作了讨论，最后介绍了指南。     

口服环孢素A治疗9例银屑病小结

口服环孢素Ａ治疗９例银屑病小结严煜林，韦高，李菊裳１９９２年４月至１９９３竿６月，我们使用瑞士Ｓａｎｄｏｚ医药公司的口服用环孢素Ａ（ＣＳＡ）治疗９例银屑病，现小结如下。１资料与方法１．１病例资料：所有患者均为住院治疗；９例均为男性；年龄２７～５６岁（...     

银屑病患者甲下裂片形出血一例

患者男,35岁.因双手指部分甲板远端分离并出现黑褐色线状出血带2个月,于2008年8月就诊.患者有银屑病史7年,皮损冬重夏轻,家族成员中无银屑病发病史.患者平素体健,否认局部外伤史,银屑病一直以外用药治疗为主,近期无系统用药史.     

Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab

Erythrodermic psoriasis is a severe, life‐threatening condition with additional complications, when occurring in hemodialyzed patients, as the majority of treatments are contraindicated. A 44‐years‐old man, of Philippine origins, with a 15‐years‐history of psoriasis treated with cyclosporine developed progressive hypertension and renal insufficiency. Despite drug dismission, renal function worsen to end‐stage, and hemodialysis was necessary three times a week. Phototherapy was not able to control the skin condition, progressing to erythroderma, and after nephrology consultation, the patient consent to the off‐label secukinumab treatment, at the standard regimen (300 mg subcutaneously once weekly at weeks 0‐4 followed by 300 mg every 4 weeks). Seven days after the first injection, a rapid improvement was noted, with the psoriasis area severity index (PASI) score passing from 31.5 to 17.6. At the 52‐week‐follow‐up visit, the patient was completely clarified, without any side effects. The case supports secukinumab effectiveness and safety in difficult patients, including erythrodermic psoriasis with end‐stage renal failure, as drug plasma levels seem not to be affected by hemodialysis. Results are rapidly achieved, and long term maintained, with the additional advantage of a very comfortable monthly administration.     

A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis

We report a case of a 25‐year‐old Chinese man with an exceptionally prolonged history of pustular psoriasis derived from inverse psoriasis who was unsatisfied with conventional treatment and was successfully treated with a single dose of infliximab without noticeable adverse effects. No recurrence or flaring was observed after 3 months of follow‐up. This case illustrates that infliximab may be an effective and safe therapeutic option for patients with refractory pustular psoriasis derived from inverse psoriasis.     

Photosensitive psoriasis in a vitiligo patient

We report a case of a 15-year-old Caucasian female, previously affected by non-segmental vitiligo and psoriasis vulgaris, who developed a psoriatic eruption on sun-exposed skin during the summer. Oral therapy with cyclosporine A achieved a rapid improvement of the clinical picture. The main features of photosensitive psoriasis and the association between psoriasis and vitiligo are discussed herein.     

Ichthyosis and psoriasis in a patient with Down syndrome.

A 24-year-old man with Down syndrome presented with prominent ichthyosiform skin on his extremities and psoriatic plaques on his chest, back and scalp. The late onset of his ichthyosis without family history suggested that it was not a heritable form but was associated Down syndrome. Such an association with ichthyosis and psoriasis has not been described previously.     

生存素在寻常型银屑病皮损中的表达

目的：探讨生存素（survivin）在银屑病皮损中的表达及意义。方法：应用免疫组织化学技术（IHC）检测38例寻常型银屑病患者皮损与14例正常人皮肤中生存素的表达。结果：36例银屑病皮损中可检测到生存素,而正常皮肤无生存素表达,生存素在进行期皮损中的表达高于稳定期。结论：生存素可能参与了银屑病的发病过程。     

Benign intracranial hypertension in a patient treated with ustekinumab for psoriasis

Ustekinumab is a monoclonal antibody, which binds the p40 subunit of IL‐12 and IL‐23 so they are unable to bind to their receptors, ultimately reducing T‐cell‐mediated inflammation in psoriasis. Studies and cases have focused on the risk of infection and malignancy associated with the use of biologics medications; however, there have been limited data available on the potential neurological adverse effects of biologics. We report the case of a 44‐year‐old female with a longstanding history of psoriasis who developed benign intracranial hypertension while on ustekinumab for her psoriasis.